MDM2 and neuroblastoma: To compare the effect of WIP1 inhibition with the effect of alternative indirect p53 reactivation, a panel of eleven neuroblastoma and six medulloblastoma/sPNET cell lines were treated with different concentrations of SL-176, the p53 modulator RITA, and the MDM2 antagonist Nutlin-3.